Mauritius has confirmed 2,816 locally-acquired chikungunya cases between January and 11 May 2026 — its first since 2009 — prompting a CDC Level-2 travel notice recommending enhanced precautions and vaccination.
The last time Mauritius had to think about chikungunya, the financial crisis was still in living memory and the iPhone 3GS had just launched. The country reported its previous outbreak in 2009 and then went seventeen years without a locally-acquired case. That run ended in January 2026. By 11 May, the Mauritian Ministry of Health and Wellness had confirmed 2,816 locally-acquired chikungunya cases across the island, concentrated in the lower and middle Plaines Wilhems district. Three days later, on 14 May, the US Centers for Disease Control and Prevention escalated the situation to a Level-2 travel health notice — the formal "practice enhanced precautions" tier — and recommended vaccination for travellers visiting affected areas.
Mauritius is a tourist economy. It receives somewhere north of a million international visitors a year, mostly from France, India, Réunion, South Africa, and the United Kingdom. Mosticare's readership includes a non-trivial fraction of people who will fly to Mauritius this summer, this winter, or the one after. The 14 May CDC notice is the single most useful pre-travel document published about the island this quarter, and what it says deserves to be read carefully.
What is actually happening on the island
The Mauritian outbreak is being driven by Aedes albopictus — the Asian tiger mosquito — rather than by Aedes aegypti, the more famous urban arbovirus vector. Ae. albopictus is established widely across Mauritius and has been the principal local chikungunya vector since the island's last major outbreak, in 2005–2006, when the virus moved through the Western Indian Ocean and infected an estimated one-third of Réunion's population. The species bites by day and at dusk, breeds in small water containers (plant saucers, tyres, blocked guttering, animal-feeding bowls), and tolerates a wider temperature range than Ae. aegypti. It does not require dense urban tropical conditions to sustain transmission.
The case curve since January has run in one direction. February's count exceeded January's; March and April continued the climb; the May data through the 11th — the cut-off the Ministry of Health used for the figure CDC cited — already put cumulative cases past 2,800. Geographic concentration in the lower and middle Plaines Wilhems district matters because Plaines Wilhems contains some of the island's most densely-populated communes — Curepipe, Vacoas-Phoenix, Quatre Bornes, Beau Bassin-Rose Hill — and is the part of the country where European tourists are most likely to overnight in the central plateau between the airport and the coastal resorts.
The other detail worth attention is the viral lineage. Preliminary phylogenetic work circulating on ResearchGate frames the 2026 Mauritius outbreak as driven by a "novel lineage with pandemic potential". The framing is not yet peer-reviewed at editorial-quality grade, but the underlying observation — that the chikungunya strain circulating in Mauritius is not a straightforward re-import of the 2024–2025 Réunion lineage — is consistent with the genuine concern that has driven CDC's choice of a Level-2 advisory rather than the lower-tier "usual precautions" advisory most island outbreaks receive.
The Western Indian Ocean is now a multi-island arc
Mauritius is one node in a four-island chikungunya pattern that has now run for roughly eighteen months.
Réunion experienced a substantial outbreak across 2024 and into mid-2025, with cumulative cases running into the hundreds of thousands by epidemiologists' provisional counts. Réunion is a French overseas department and was the original European-administered foothold for chikungunya during the 2005–2006 Indian Ocean epidemic; its 2024–2025 cycle reactivated the region's vector-control machinery and put traveller-imported cases on Santé publique France's daily watch.
Mauritius is now the second island to fall into active local transmission. CDC's 14 May notice is the formal recognition that the country has crossed the threshold from "imported risk" to "endemic outbreak."
Mayotte, also a French overseas department in the Mozambique Channel, has reported a renewed increase in case numbers since epidemiological week 3 of 2026 — earlier in the year than its usual seasonal pattern.
Madagascar reported 29 confirmed chikungunya cases through epidemiological week 6 of 2026, concentrated in three regions: Mahajanga (highest concentration), Toamasina, and Antsirabe.
Read as a single regional story, the Western Indian Ocean chikungunya axis is now an eighteen-month, four-territory event. None of these islands is geographically far from any other. The ECDC monthly chikungunya bulletins are the cleanest single source for the joined-up regional picture, and Mosticare's editorial position is that anyone tracking either Mauritius travel risk or European traveller-imported transmission should be reading the ECDC monthly first.
What the CDC notice actually recommends
The Level-2 notice is built around four practical pieces of advice. None of them is novel; all of them are unimprovable.
Vaccination. A chikungunya vaccine is now licensed in several jurisdictions including the United States and parts of Europe. CDC recommends vaccination for travellers visiting outbreak areas, with the standard caveat that pregnant travellers should defer vaccination until after delivery unless the risk of infection is high and unavoidable. Travellers should consult a travel-medicine practitioner six to eight weeks ahead of departure to allow the immune response to develop and to permit a discussion of contraindications.
Insect repellent. The standard CDC advice — DEET, picaridin, IR3535, or oil of lemon eucalyptus — applied to all exposed skin and to clothing where appropriate. Aedes albopictus bites by day, so application discipline matters from morning to early evening, not just at dusk.
Clothing. Long sleeves and long trousers. Ae. albopictus will bite through tight-fitting fabric, but loose long-sleeved clothing is materially harder for the mosquito to access than bare skin or shorts.
Accommodation. Air-conditioning or intact screens on windows and doors. Mauritian luxury resorts overwhelmingly meet both criteria. Smaller guesthouses, self-catering apartments, and the central-plateau hotel stock where some travellers stay between the airport and the coast vary more — this is the question most worth asking the accommodation provider ahead of booking.
The personal-protection layer most worth investing in for a Mauritius trip this year is the structural one — the screened or air-conditioned room, the long-sleeved evening clothing, the vaccine done in advance — rather than the aerosol can. Repellent works, but it works for hours; the room and the vaccine work for the trip.
What to watch next
Three signals are worth tracking through the rest of 2026.
The first is whether the Mauritius case curve crests in May or continues into the southern-hemisphere winter. The 11 May Ministry of Health cut-off captures the first phase; the late-May and June numbers will tell us whether the outbreak is following the typical Indian Ocean seasonal pattern or extending past it.
The second is European traveller-imported transmission. The 2025 European autochthonous chikungunya cluster pattern, documented across France's eight transmission régions in last summer's Bilan, was seeded by traveller-imported cases from the Western Indian Ocean. With Mauritius, Réunion, Mayotte, and Madagascar all active simultaneously, the 2026 European import volume is going to be higher than 2025's was. France's Santé publique France 1 May 2026 surveillance activation, covered in Mosticare's 26 May piece, is partly an institutional response to this exact dynamic.
The third is the viral lineage characterisation. If the preliminary "novel lineage with pandemic potential" framing holds up under peer review, the editorial register of the next six months of chikungunya coverage will change. If it does not, the Mauritius outbreak will sit in the same continuum as the 2005–2006 Indian Ocean epidemic — a serious, geographically-circumscribed event that the standard combination of vector control, traveller advisories, and the now-available vaccine can hold.
What we know
- 2,816 locally-acquired chikungunya cases confirmed in Mauritius between 1 January and 11 May 2026 — the first since 2009 (Mauritius Ministry of Health & Wellness, via Outbreak News Today).
- CDC issued a Level-2 travel health notice on 14 May 2026 recommending enhanced precautions and vaccination for travellers (CDC).
- Vector: Aedes albopictus, the Asian tiger mosquito — established island-wide; bites by day and at dusk.
- Geographic concentration: lower and middle Plaines Wilhems district, including Curepipe, Vacoas-Phoenix, Quatre Bornes, and Beau Bassin-Rose Hill.
- Regional context: Mauritius is one node in a four-territory Western Indian Ocean chikungunya pattern alongside Réunion (2024–2025), Mayotte (resurgence from week 3 of 2026), and Madagascar (29 cases through week 6, concentrated in Mahajanga, Toamasina, and Antsirabe).
Sources cited
- CDC, Chikungunya in Mauritius (Level-2 Travel Health Notice), reviewed 14 May 2026 — https://wwwnc.cdc.gov/travel/notices/level2/chikungunya-mauritius
- Outbreak News Today, Chikungunya in Mauritius: 2,800 confirmed cases in 2026 — https://outbreaknewstoday.substack.com/p/chikungunya-in-mauritius-2800-confirmed
- European Centre for Disease Prevention and Control, Chikungunya virus disease worldwide overview (monthly) — https://www.ecdc.europa.eu/en/chikungunya-monthly
- Travel Doctor TMVC, Chikungunya outbreak in Mauritius — https://traveldoctor.com.au/health-alerts/chikungunya-outbreak-mauritius